Citations

Clear

511 citation(s) found for "Seth, N".

Association of CMB305 or LV305-induced and baseline anti-NY-ESO-1 immunity with survival in recurrent cancer patients.
Somaiah, Neeta , Chawla, Sant P. , Morris, John C. , Tu, Khanh, Block, Matthew S. , Yusko, Erik, Hsu, Frank J., Bohac, Gerry C., Gnjatic, Sacha , Meulen, Jan ter , Gnjatic, Sacha , Pollack, Seth M. , Lu, Hailing , Kim, Joseph W. , Vignali, Marissa , Rytlewski, Julie

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 3090-3090

10.1200/jco.2017.35.15_suppl.3090 Get It

3090 Background: The correlation of immune response (IR) and clinical benefit in patients (pts) who receive active immunotherapy remains controversial. CMB305 is an active immunotherapy designed to generate and expand anti-NY-ESO-1 T cells, consisting of LV305 (a DC targeting lentiviral vector encoding NY-ESO-1) and a boost (NY-ESO-1 recombinant protein plus GLA-SE, a TLR-4 agonist). Phase 1 studies of LV305 and CMB305 evaluated the IR and survival of pts with NY-ESO-1 positive tumors. Methods: 62 pts with recurrent NY-ESO-1 expressing (by IHC) solid tumors were enrolled in 2 Phase 1 trials (31 pts each: 43 sarcomas, 12 ovarian, 4 melanomas, and 3 NSCLC). Peripheral blood was assessed pre and post therapy for anti-NY-ESO-1 T cell responses (IFNγ ELISPOT) and antibodies (Ab) (ELISA) (n = 62), TCR-β CDR3 repertoire and conserved (public) TCR (n = 28), and antigen spreading (ELISA, ELISPOT) (n = 23). Relationship between progression-free survival (PFS), overall survival (OS) and up to 15 biomarkers were analyzed by the Kaplan-Meier method. Results: Preexisting anti-NY-ESO-1 T cells and Ab were identified in 34% and 40% of pts. LV305 and CMB305 induced (de novo or increased) anti-NY-ESO-1 T-cells in 51% and 65% pts, and anti-NY-ESO-1 Ab responses in 13% and 68% pts, respectively. LV305 and CMB305 induced antigen spreading in 17% and 36% pts. TCR clonality increased after CMB305 as compared to LV305. The TCRβ-CDR3 amino acid sequences of three NY-ESO-1 specific TCR clones in a patient with a > 2-year response were fully conserved in 20/28 patients. Biomarkers showing the strongest association with OS and PFS were pre-existing anti-NY-ESO-1 T-cell response and Ab, integrated IR (T cells and antibodies), and NY-ESO-1 expression level. Presence of public TCRs was associated with longer survival, particularly in pts with high ( > 50%) NY-ESO-1 expression. Conclusions: While LV305 and CMB305 are both immunogenic, CMB305 resulted in a stronger and broader integrated IR, including antigen spreading. The three identified survival variables, preexisting and treatment-induced NY-ESO-1 IR and the presence of public TCRs, warrant validation in randomized studies of CMB305.
SARC016: Phase II study of everolimus in combination with bevacizumab in sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST).
Widemann, Brigitte C. , Meyer, Christian F. , Tine, Brian Andrew Van, Turpin, Brian , Jayaprakash, Nalini, Okuno, Scott H. , Helman, Lee J. , Onwudiwe, Ndidi, Steinberg, Seth M. , Coté, Gregory M. , Chugh, Rashmi , Milhem, Mohammed , Kim, AeRang , Dombi, Eva , Reinke, Denise K. , Cichowski, Karen , Perentesis, John P.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 11053-11053

10.1200/jco.2016.34.15_suppl.11053 Get It

Single-agent LV305 to induce anti-tumor immune and clinical responses in patients with advanced or metastatic sarcoma and other cancers expressing NY-ESO-1.
Somaiah, Neeta , Block, Matthew S. , Tu, Khanh, Hwu, Patrick , Jones, Robin L. , Gnjatic, Sacha , Lu, Hailing , Meulen, Jan ter , Hsu, Frank J., Gnjatic, Sacha , Jones, Robin L , Kim, Joseph W. , Shapiro, Geoffrey I. , Eder, Joseph P. , Pollack, Seth M.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 3093-3093

10.1200/jco.2016.34.15_suppl.3093 Get It

Double blind phase III trial of effects of low dose 13-cisretinoic acid on prevention of second primaries in stages I-II head and neck cancer: A trial of the ECOG-ACRIN Cancer Research Group (C0590).
Bhatia, Aarti , Lee, Ju‐Whei , Pinto, Harlan , Jacobs, Charlotte, Arusell, Robert M., Dunphy, Eamonn P., Khandekar, Janardan D., Reiner, Seth, Báez-Díaz, Luis , Celano, Paul , Li, Yi , Pandya, Kishan J., Pinto, Harlan A. , Limburg, Paul J. , Li, Shuli , Burtness, Barbara

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 1507-1507

10.1200/jco.2016.34.15_suppl.1507 Get It

Effect of anti-CTGF human recombinant monoclonal antibody pamrevlumab on resectability and resection rate when combined with gemcitabine/nab-paclitaxel in phase 1/2 clinical study for the treatment of locally advanced pancreatic cancer patients.
Picozzi, Vincent J. , Pishvaian, Michael J. , Mody, Kabir , Larson, Tim , Matrana, Marc , Saikali, Khalil G., Carney, Mairead, Porter, Seth, Yu, Peony, Kouchakji, Elias, Carrier, Ewa , Winter, Jordan Michael , Glaspy, John A. , Larson, Tim

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 4016-4016

10.1200/jco.2018.36.15_suppl.4016 Get It

Hepatocellular Carcinoma Detection by Plasma Methylated DNA: Discovery, Phase I Pilot, and Phase II Clinical Validation
Dukek, Brian A. , Kanipakam, Reddappa V.S.R., Ghoz, Hassan , Yab, Tracy C. , Giama, Nasra H., Onyirioha, Kristeen, Abdallah, Mohamed A., Burger, Kelli N. , Slettedahl, Seth W. , Smyrk, Thomas C. , Lewis, Jason T., Giakoumopoulos, Maria , Allawi, Hatim T. , Lidgard, Graham P. , Roberts, Lewis R. , Ahlquist, David A. , Kisiel, John B. , V S R Kanipakam, Reddappa, Ghoz, Hassan M, Berger, Calise K. , Foote, Patrick H. , Mahoney, Douglas W. , Roberts, Lewis R , Slettedahl, Seth W , Taylor, William R. , Abdallah, Mohamed A., Lewis, Jason T.

Mayo Clinic

Hepatology | August 31, 2018 | Volume: 69 | Issue: 3 | Pages: 1180-1192

10.1002/hep.30244 | PMID 30168613 Get It

Early detection improves hepatocellular carcinoma (HCC) outcomes, but better noninvasive surveillance tools are needed. We aimed to identify and validate methylated DNA markers (MDMs) for HCC detection. Reduced representation bisulfite sequencing was performed on DNA extracted from 18 HCC and 35 control tissues. Candidate MDMs were confirmed by quantitative methylation‐specific PCR in DNA from independent tissues (74 HCC, 29 controls). A phase I plasma pilot incorporated quantitative allele‐specific real‐time target and signal amplification assays on independent plasma‐extracted DNA from 21 HCC cases and 30 controls with cirrhosis. A phase II plasma study was then performed in 95 HCC cases, 51 controls with cirrhosis, and 98 healthy controls using target enrichment long‐probe quantitative amplified signal (TELQAS) assays. Recursive partitioning identified best MDM combinations. The entire MDM panel was statistically cross‐validated by randomly splitting the data 2:1 for training and testing. Random forest (rForest) regression models performed on the training set predicted disease status in the testing set; median areas under the receiver operating characteristics curve (AUCs; and 95% confidence interval [CI]) were reported after 500 iterations. In phase II, a six‐marker MDM panel (homeobox A1 [HOXA1], empty spiracles homeobox 1 [EMX1], AK055957 , endothelin‐converting enzyme 1 [ECE1], phosphofructokinase [PFKP], and C‐type lectin domain containing 11A [CLEC11A]) normalized by beta‐1,3‐galactosyltransferase 6 (B3GALT6) level yielded a best‐fit AUC of 0.96 (95% CI, 0.93‐0.99) with HCC sensitivity of 95% (88%‐98%) at specificity of 92% (86%‐96%). The panel detected 3 of 4 (75%) stage 0, 39 of 42 (93%) stage A, 13 of 14 (93%) stage B, 28 of 28 (100%) stage C, and 7 of 7 (100%) stage D HCCs. The AUC value for alpha‐fetoprotein (AFP) was 0.80 (0.74‐0.87) compared to 0.94 (0.9‐0.97) for the cross‐validated MDM panel (P < 0.0001). Conclusion : MDMs identified in this study proved to accurately detect HCC by plasma testing. Further optimization and clinical testing of this promising approach are indicated.
Expression of RAD21 immunoreactivity in myenteric neurons of the human and mouse small intestine
Bianco, Francesca , Eisenman, Seth T., Aguilar, Maria Gabriela Colmenares , Bonora, Elena , Clavenzani, Paolo , Linden, David R. , Giorgio, Roberto De , Farrugia, Gianrico , Gibbons, Simon J. , Linden, D R , De Giorgio, R , Gibbons, S J

Mayo Clinic

Neurogastroenterology & Motility | August 3, 2018 | Volume: 30 | Issue: 9 | Pages: No page available

10.1111/nmo.13429 | PMID 30069982 Get It

AbstractBackgroundRAD21 is a double‐strand‐break repair protein and component of the cohesin complex with key roles in cellular functions. A RAD21 loss‐of‐function mutation was found in cases of chronic intestinal pseudo‐obstruction (CIPO) with associated enteric neuronal loss. Analysis of RAD21 expression in the enteric nervous system is lacking, thus we aimed to characterize RAD21 immunoreactivity (IR) in myenteric ganglia.MethodsDouble labeling immunofluorescence in mouse and human jejunum was used to determine colocalization of RAD21 with HuC/D, PGP9.5, neuronal nitric oxide synthase (nNOS), neuropeptide Y (NPY), choline acetyl transferase (ChAT), Kit, platelet‐derived growth factor receptor‐α (PDGFRα), and glial fibrillary acid protein (GFAP) IRs.ResultsA subset of PGP9.5‐ and HuC/D‐IR neuronal cell bodies and nerve fibers in the myenteric plexus of human and mouse small intestine also displayed cytoplasmic RAD21‐IR Cytoplasmic RAD21‐IR was found in 43% of HuC/D‐IR neurons in adult and neonatal mice but did not colocalize with nNOS. A subset of ChAT‐positive neurons had cytoplasmic RAD21‐IR Punctate RAD21‐IR was restricted to the nucleus in most cell types consistent with labeling of the cohesin complex. Cytoplasmic RAD21‐IR was not detected in interstitial cells of Cajal, fibroblast‐like cells or glia. Subsets of neurons in primary culture exhibited cytoplasmic RAD21‐IR Suppression of RAD21 expression by shRNA knockdown abolished RAD21‐IR in cultured neurons.ConclusionsOur data showing cytoplasmic RAD21 expression in enteric neurons provide a basis toward understanding how mutations of this gene may contribute to altered neuronal function/survival thus leading to gut‐motor abnormalities.
Inhaled TRIM72 Protein Protects Ventilation Injury to the Lung through Injury-guided Cell Repair
Nagre, Nagaraja N. , Cong, Xiaofei, Fu, Hongyun , Pepper, Ian, Warren, Seth , Sill, Joshua , Hubmayr, Rolf D., Zhao, Xiaoli , Ji, Hong‐Long , Schreiber, John R. , Fu, Hongyun

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | June 29, 2018 | Volume: 59 | Issue: 5 | Pages: 635-647

10.1165/rcmb.2017-0364oc | PMID 29958015 Get It

Abstract Studies showed that TRIM72 is essential for repair of alveolar cell membrane disruptions, and exogenous recombinant human TRIM72 protein (rhT72) demonstrated tissue-mending properties in animal models of tissue injury. Here we examine the mechanisms of rhT72-mediated lung cell protection in vitro and test the efficacy of inhaled rhT72 in reducing tissue pathology in a mouse model of ventilator-induced lung injury. In vitro lung cell injury was induced by glass beads and stretching. Ventilator-induced lung injury was modeled by injurious ventilation at 30 ml/kg tidal volume. Affinity-purified rhT72 or control proteins were added into culture medium or applied through nebulization. Cellular uptake and in vivo distribution of rhT72 were detected by imaging and immunostaining. Exogenous rhT72 maintains membrane integrity of alveolar epithelial cells subjected to glass bead injury in a dose-dependent manner. Inhaled rhT72 decreases the number of fatally injured alveolar cells, and ameliorates tissue-damaging indicators and cell injury markers after injurious ventilation. Using in vitro stretching assays, we reveal that rhT72 improves both cellular resilience to membrane wounding and membrane repair after injury. Image analysis detected rhT72 uptake by rat alveolar epithelial cells, which can be inhibited by a cholesterol-disrupting agent. In addition, inhaled rhT72 distributes to the distal lungs, where it colocalizes with phosphatidylserine detection on nonpermeabilized lung slices to label wounded cells. In conclusion, our study showed that inhaled rhT72 accumulates in injured lungs and protects lung tissue from ventilator injury, the mechanisms of which include improving cell resilience to membrane wounding, localizing to injured membrane, and augmenting membrane repair.
Gastrointestinal: Hide‐bound bowel
Hoversten, Patrick , Bledsoe, Adam C. , Sweetser, Seth

Mayo Clinic

Journal of Gastroenterology and Hepatology | June 6, 2018 | Volume: 33 | Issue: 8 | Pages: 1433-1433

10.1111/jgh.14283 | PMID 29873115 Get It

Detection of Gastric Cancer with Novel Methylated DNA Markers: Discovery, Tissue Validation, and Pilot Testing in Plasma
Anderson, Bradley W., Suh, Yun‐Suhk , Choi, Boram , Lee, Hyuk‐Joon , Yab, Tracy C. , Dukek, Brian A. , Cao, Xiaoming , Devens, Mary E., Boardman, Lisa A., Slettedahl, Seth W. , Allawi, Hatim T. , Lidgard, Graham P. , Smyrk, Thomas C. , Yang, Han‐Kwang , Ahlquist, David A. , Berger, Calise K. , Foote, Patrick H. , Kisiel, John B. , Mahoney, Douglas W. , Slettedahl, Seth W , Taylor, William R. , Boardman, Lisa A.

Mayo Clinic

Clinical Cancer Research | May 29, 2018 | Volume: 24 | Issue: 22 | Pages: 5724-5734

10.1158/1078-0432.ccr-17-3364 | PMID 29844130 Get It

Abstract Purpose: Gastric adenocarcinoma is the third most common cause of cancer mortality worldwide. Accurate and affordable noninvasive detection methods have potential value for screening and surveillance. Herein, we identify novel methylated DNA markers (MDM) for gastric adenocarcinoma, validate their discrimination for gastric adenocarcinoma in tissues from geographically separate cohorts, explore marker acquisition through the oncogenic cascade, and describe distributions of candidate MDMs in plasma from gastric adenocarcinoma cases and normal controls. Experimental Design: Following discovery by unbiased whole-methylome sequencing, candidate MDMs were validated by blinded methylation-specific PCR in archival case–control tissues from U.S. and South Korean patients. Top MDMs were then assayed by an analytically sensitive method (quantitative real-time allele-specific target and signal amplification) in a blinded pilot study on archival plasma from gastric adenocarcinoma cases and normal controls. Results: Whole-methylome discovery yielded novel and highly discriminant candidate MDMs. In tissue, a panel of candidate MDMs detected gastric adenocarcinoma in 92% to 100% of U.S. and South Korean cohorts at 100% specificity. Levels of most MDMs increased progressively from normal mucosa through metaplasia, adenoma, and gastric adenocarcinoma with variation in points of greatest marker acquisition. In plasma, a 3-marker panel (ELMO1, ZNF569, C13orf18) detected 86% (95% CI, 71–95) of gastric adenocarcinomas at 95% specificity. Conclusions: Novel MDMs appear to accurately discriminate gastric adenocarcinoma from normal controls in both tissue and plasma. The point of aberrant methylation during oncogenesis varies by MDM, which may have relevance to marker selection in clinical applications. Further exploration of these MDMs for gastric adenocarcinoma screening and surveillance is warranted. Clin Cancer Res; 24(22); 5724–34. ©2018 AACR.